Focusing on the development and production of modern traditonal chinese medicine and high-end sustained release formulations, Baheal Pharma folows the moderimedical theory guidelines, emphasizes self-innovation and features high-end sustained-release formula techology. Holding onto the philosophy that diseases can bediagnoed, quality can be controled, and effects can be evaluated, it manufactures inovative products of chinese and Western medicine with independent intelectualproperty rights.

RDO Technoloay is committed to providing comprehensive solutions for nuclear medicine molecular imaqing and treatment, Specializing in develop-ing internationally top-level radioactive drugs with independent intellectual property rights, RDO also propels equipment innovation through druginnovation, developing SPECT/CT with independent intellectual property rights, By integrating medicine and equipment, it offers the society safer,more economical, and more effective nuclear medicine products and services.

RabPharma is an innovative medical R&D platform company focusing on incurable orthopedic diseases. Spurred by an unsatisfying clinical medication demand in China and all over the world, the company has researched original new medicines with “First-in-class” or “Best-in-class” potential.

Beijing Enrini Biotechnology Co., Ltd. is a biomedical platform company which integrates the research and development of new medicines, technical services, and industrialization. The company focuses on the R&D of anti-neoplastic innovative medicines and strives to create a global biomedical enterprise.

Founded in 2008, CH Biomedical is dedicated to independently developing, manufacturing and promoting the world’s state-of-the art ventricular assist devices (VADs) to enable a wider range of heart failure patients and their families to return to a healthy and happy life by continuing to provide exceptional service to professional medical teams and patients.
With its technological accumulation in the field of totally magnetically levitated VADs, CH Biomedical has developed Vinovi™, which became the first totally magnetically levitated VAD to be approved in China. The company has a comprehensive patent portfolio based on this product in China, the United States, Europe and Japan. In light of the latest breakthroughs in key clinical performance indicators of this product, the company is recognized as technology innovator among international VAD community.
The company is committed to promoting continuous innovation in the VAD industry by creating shared values which harnesses the resources and skills on a global scale. With the high-threshold technology platform and the establishment of product and service standardization will lay a solid foundation for the sustainable development of the company in China and overseas, and become a next generation leader in the global VAD industry.

Relying on its state-level scientific research team, Huake Pioneer is a high-end science & technology company at the core of world-class research. Focusing on the research and manufacture of full circumferential spherical stereotactic radiotherapy systems, the company provides radiotherapy solutions for systemic tumors.

Medis Medical, specializing in minimally invasive and precisionhas broken throuah the 'Bottleneck' technology of electromagnetic naviga.treatment so utions.tion. By independently developing an algorithm, it can sustain the electromagnetic navigating system, achieving the fusion of electromagnetic positioning anduitrasound images, It has now developed the first domesticaly and intemationaly leading ultrasound electromagnetic positioning puncture quiding device

Wehealth Inc. is committed to providing global users with a cardiovascular health monitoring, early warning, and management service system based on mobile internet and intelligent hardware. The company possesses independently developed software and hardware products and technical achievements and has obtained multiple national patents, making it a leading enterprise in this field.

Baheal Wisart is an innovative high-tech company which is led by pioneering biomedical research and achievements in technological transformation. Based on its cooperation with the National Center for Cardiovascular Diseases, Fuwai Hospital, and the Chinese Academy of Medical Sciences, the company has conducted research on human primary cardiac myocytes and has world-class technologies for storing, separating, culturing, and freezing human primary cardiac myocytes.

Baheal Glycomtech is dedicated to researching polysaccharides, the Glyco-proteome, andthe Glyco-transcriptome. We are committed ourselves to identifying critical targets and bio-markers associated with maior diseases such as malignant tumors, cardiovascular diseas-es, autoimmune diseases, and neurodegenerative diseases.

Calusly Multi-0rgan-0n-a-Chip is a cutting-edde micro-physiological svstem desianed with personalized precision medicine inmind. It provides a versatile, replicable, and in vitro miniaturized model of human organ systems. This platform is indispensablefor research into organ function, unraveling disease pathwavs, identifying biological targets, and creating specialized therapeuticdrugs.

Through cooperation with national research institutes and independent research, Baheal Bio-Diagnostics focuses on diagnostic services and clinical translations for early screening, companion diagnosis and precision treatment of severe diseases, by employingmolecularandimmunological technologies.